Market Overview

Robbins Arroyo LLP: Viability of Acadia Pharmaceuticals, Inc. (ACAD) Drug NUPLAZID Questioned by Recently Filed Class Action

Share:

Shareholder rights law firm Robbins
Arroyo LLP
announces that purchasers of Acadia Pharmaceuticals, Inc.
(NASDAQ:ACAD) have filed a class action complaint against the
company's officers and directors for alleged violations of the
Securities Exchange Act of 1934 between April 29, 2016 and July 9, 2018.
Acadia Pharmaceuticals is a biopharmaceutical company that focuses on
the development and commercialization of drugs for central nervous
system disorders. The company's lead drug is NUPLAZID, which was
approved by the U.S. Food and Drug Administration on April 29, 2016, for
the treatment of hallucinations and delusions associated with
Parkinson's disease psychosis.

View this information on the law firm's Shareholder Rights Blog: https://www.robbinsarroyo.com/acadia-pharmaceuticals-july-2018/

Acadia Pharmaceuticals Accused of Making Materially False and
Misleading Statements Regarding its Lead Drug Candidate

According to the complaint, throughout the class period, Acadia
Pharmaceuticals touted the positive impact of NUPLAZID on its financial
growth. On April 9, 2018, CNN reported that "[p]hysicians, medical
researchers and other experts … [are] worried that [NUPLAZID] had been
approved too quickly, based on too little evidence that it was safe or
effective. And given these mounting reports of deaths, they say that
more needs to be done to assess Nuplazid's true risks." On April 25,
2018, CNN reported that the FDA was re-examining the safety of NUPLAZID.
On July 9, 2018, the Southern Investigative Reporting Foundation
("SIRF") reported that "evidence is mounting that something is horribly
wrong with Acadia's sole drug, Nuplazid" and that "Acadia has
accomplished its growth in ways that have attracted intense regulatory
scrutiny for other drug companies" including "dispensing wads of cash to
doctors to incentivize prescription writing and downplaying mounting
reports of patient deaths." Since the concern over the safety of
NUPLAZID has become public, the stock has dropped approximately 25%.

Acadia Shareholders Have Legal Options

If you would like more information about your rights and potential
remedies, contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com,
or via the shareholder
information form
on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder
rights law. The firm represents individual and institutional investors
in shareholder derivative and securities class action lawsuits, and has
helped its clients realize more than $1 billion of value for themselves
and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

View Comments and Join the Discussion!